Pharmafile Logo
Pharmafocus logo
Advanced Search

ulcerative colitis

Showing 15 posts of 30 posts found.

Pfizer’s Velsipity approved by EC for ulcerative colitis treatment

February 20, 2024
Medical Communications European Commission, Gastrointestinal tract, Pfizer, Velsipity, ulcerative colitis

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) in the European Union (EU). …

News

Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment

November 23, 2023
Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …

News

Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment

October 27, 2023
Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …

News
louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

October 4, 2023
Medical Communications Crohn’s disease, Gastrointestinal tract, Sanofi, Teva, bowel disease, ulcerative colitis

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation of TEV’574, a treatment for …

News

OSE Immunotherapies’ UC drug gets DSMB positive recommendation

July 6, 2023
Research and Development EMA, Gastrointestinal tract, OSE Immunotherapeutics, ulcerative colitis

French biotech company OSE Immunotherapeutics has announced that its Ulcerative Colitis (UC) trial’s Independent Drug Safety Monitoring Board (DSMB) has provided …

News

Amsterdam UMC’s new drug doubles remission rates in patients with ulcerative colitis

July 4, 2023
Research and Development Amsterdam UMC, Gastrointestinal tract, mirikizumab, ulcerative colitis

A new drug, being investigated by Amsterdam UMC along with colleagues at various universities, has been shown to be effective …

News
Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

News
roche

Roche’s entrolizumab disappoints at Phase 3 in moderately to severely active ulcerative colitis

August 11, 2020
Manufacturing and Production, Research and Development Roche, etrolizumab, trial failure, ulcerative colitis

Roche has voiced its disappointment after its investigational therapy etrolizumab showed “mixed results” as a treatment for moderately to severely …

News
takeda_usa_pharmaceuticals_u

Takeda’s subcutaneous Entyvio approved in Europe for maintenance of moderate to severe Crohn’s and ulcerative colitis

May 11, 2020
Sales and Marketing Crohn’s disease, Entyvio, Takeda, crohn's disease, ulcerative colitis

The European Commission has awarded marketing approval to Takeda’s subcutaneous formulation of its gut-selective biologic therapy Entyvio (vedolizumab) as a …

News
janssen_latest_logo_on_sign_closer

NICE backtracks to approve Janssen’s Stelara in ulcerative colitis

April 28, 2020
Manufacturing and Production, Research and Development Janssen, NICE, Stelara, ulcerative colitis

NICE has recommended Janssen’s Stelara (ustekinumab) for the treatment of moderately to severely active ulcerative colitis (UC), a move which …

News

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …

News
takeda_deerfield_hq

Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

September 27, 2019
Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha …

News
janssen_latest_logo_on_sign_closer

Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis

September 5, 2019
Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis

Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …

News
takeda_usa_pharmaceuticals_u

Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

May 20, 2019
Research and Development, Sales and Marketing AbbVie Humira, Entyvio, Takeda, pharma, ulcerative colitis

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its …

News
janssen_latest_logo_on_sign_closer

Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials

March 13, 2019
Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis

Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024